Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.8 USD | +0.26% | -2.07% | +2.99% |
Apr. 25 | US FDA sends warning to Cardinal Health for marketing unapproved devices | RE |
Apr. 24 | Evercore ISI Adjusts Cardinal Health's Price Target to $110 From $118, Keeps In Line Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.99% | 25.25B | C+ | ||
+16.62% | 70.95B | C+ | ||
+5.38% | 8.67B | C | ||
+6.46% | 8.16B | B | ||
-21.01% | 7.91B | B- | ||
-0.61% | 4.51B | B- | ||
+17.12% | 4.31B | B+ | ||
-0.14% | 4.07B | B- | ||
-3.30% | 3.84B | B | ||
+21.70% | 3.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.